about
Sorafenib in advanced clear-cell renal-cell carcinomaProspective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes.Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor GroupTemsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trialAmplification of epidermal growth factor receptor gene in renal cell carcinomaPhase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinomaPreliminary results of the Prostacox phase II trial in hormonal refractory prostate cancerOpen-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-BaseBilateral Breast Metastases From Ewing Sarcoma of the Femur
P50
Q28282767-9D1D7B29-90D4-4AF7-A376-043FA1D54EEBQ33374914-C8315B24-095B-45FB-B8CF-7D0F7AD83315Q33382803-2E0587C0-A4F6-40B9-9EE1-7E785B3F3FE9Q36710452-B292960E-BE8F-4F20-BE1F-9CA496883AFCQ38082192-EC92CA56-D8B1-4ACC-A859-EACA4178C69EQ43096538-D458846F-1B6C-4728-B052-829FD3E81262Q43733824-7A516F3F-D3B3-4A60-9D86-95E7A548ADA8Q43772035-FB547038-E7B5-4945-B9E0-2AF0C6CC4BFBQ43978025-C9D4D3D6-C4F0-40B9-9982-7ECB918DFE18Q44114886-C11961A5-3108-4298-8F6F-79A89BD7DAF9Q45264009-5903A3F1-D61E-4900-AEF1-8646C9B7B1AAQ46006772-B6C30DB2-0FB9-49C6-B46E-216CF9C5DB15Q46604181-1CC1FC26-9068-4045-8C5A-FFB08FF6FC9EQ48535376-10D31060-9F41-430C-BB6F-6FB4AB388AACQ53794992-A90209B8-944B-450E-ADE5-A2ED212B79B8Q54537441-8814CA33-2313-43B9-A1E9-826F29FEAB37Q57949258-027B19BB-0595-4F34-96B1-F930F6D365FEQ57949267-E6A63835-FB7C-4959-8B9D-68F07A052C51Q57949288-2C147F7F-37B7-4984-B60A-1C658296BBF2Q57949352-CA583305-8AFE-4586-BDAD-344B0D8A8048Q57949374-9F3E3562-A05D-403A-BB59-7C1CE500CD32Q57949385-0427E86D-4BB6-476A-B800-AE904731EEC0Q57949414-626F4D0E-F96C-4F72-A68D-7263A0BA8AE0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frederic Rolland
@ast
Frederic Rolland
@en
Frederic Rolland
@es
Frederic Rolland
@nl
Frederic Rolland
@sl
type
label
Frederic Rolland
@ast
Frederic Rolland
@en
Frederic Rolland
@es
Frederic Rolland
@nl
Frederic Rolland
@sl
prefLabel
Frederic Rolland
@ast
Frederic Rolland
@en
Frederic Rolland
@es
Frederic Rolland
@nl
Frederic Rolland
@sl
P106
P21
P31
P496
0000-0001-6957-0894